1. Cell Cycle/DNA Damage
  2. Microtubule/Tubulin


Cat. No.: HY-B0628
Handling Instructions

Vinflunine is a new vinca alkaloid uniquely fluorinated with the properties of mitotic-arresting and tubulin-interacting activity.

For research use only. We do not sell to patients.
Vinflunine Chemical Structure

Vinflunine Chemical Structure

CAS No. : 162652-95-1

Size Inquiry
5 mg Get quote for price and lead time
10 mg Get quote for price and lead time
50 mg Get quote for price and lead time
100 mg Get quote for price and lead time

* Please select Quantity before adding items.

Other In-stock Forms of Vinflunine:

Other Forms of Vinflunine:

  • Biological Activity

  • Protocol

  • Technical Information

  • References


Vinflunine is a new vinca alkaloid uniquely fluorinated with the properties of mitotic-arresting and tubulin-interacting activity. Target: Microtubule/Tubulin The major effects of Vinflunine on dynamic instability are a slowing of the microtubule growth rate, an increase in growth duration, and a reduction in shortening duration. The effects of Vinflunine on the readmilling rate is examined by following [3H]GTP incorporation into MAP-rich microtubules, and the IC50 is 0.42 μM [1]. Vinflunine induced mitotic accumulation with IC50 with 18.8 nM, which decreases the centromere dynamicity by 44% and increases the time centromeres spent ina paused state by 63% [2]. Treatment of Vinflunine induces a rapid change in endothelial cell shape: cells retracts and assumes a rounded morphology. Mean IC50 values are 9.9 × 10-5 M × 10-5 M for fibronectin and 5.0× 10-5 M × 10-5 M for type IV collagen. A short 4 hours exposure of endothelial cells to Vinflunine at 10-8 0.05). An ID50 value (dose which inhibits 50% of bFGF-induced neovascularisation) is calculated as 1 mg/kg. Low doses of Vinflunine reduce the number of experimental liver metastases by human LS174T colon cancer cell. A slight overall decrease in liver metastatic foci is already observed at the very low dose of 0.16 mg/kg Vinflunine, although maximal overall inhibition is reached at the maximal tolerated dose (MTD) of 20 mg/kg [3].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02057913 Institute of Cancer Research, United Kingdom|St George's Healthcare NHS Trust Locally-advanced or Metastatic Penile Neoplasms March 2014 Phase 2
NCT01265940 Prof. Dr. Thomas Otto|Lukas-Krankenhaus GmbH Advanced Urothelial Cancer of Bladder After Failure of Platinum-containing Therapy. March 2011 Phase 1|Phase 2
NCT01599013 Pierre Fabre Medicament Bladder Transitional Cell Carcinoma Stage IV February 2011 Phase 2
NCT01830231 Associació per a la Recerca Oncologica, Spain Urothelium Transitional Cell Carcinoma October 2012 Phase 2|Phase 3
NCT00545766 SCRI Development Innovations, LLC|Bristol-Myers Squibb Prostate Cancer May 2007 Phase 2
NCT00362830 Bristol-Myers Squibb Cancer August 2006 Phase 1
NCT00388557 Bristol-Myers Squibb Cancer October 2005 Phase 1
NCT01529411 Spanish Oncology Genito-Urinary Group Carcinoma, Transitional Cell February 2012 Phase 2
NCT00284154 SCRI Development Innovations, LLC|Bristol-Myers Squibb Carcinoma, Small Cell|Lung Cancer January 2006 Phase 2
NCT00519831 UNC Lineberger Comprehensive Cancer Center|Bristol-Myers Squibb Lung Cancer August 2007 Phase 2
NCT00284180 SCRI Development Innovations, LLC|Bristol-Myers Squibb Breast Neoplasms|Breast Cancer January 2006 Phase 2
NCT00101608 Bristol-Myers Squibb|Pierre Fabre Medicament Transitional Cell Carcinoma|Bladder Neoplasms|Kidney Neoplasms|Ureter Neoplasms|Bladder Cancer|Neoplasm, Bladder January 2005 Phase 2
NCT01953003 Pierre Fabre Medicament Malignant Neoplasm of Breast September 2013 Phase 3
NCT01844947 Dr Anders Ullén|Bayer|Pierre Fabre Laboratories|Nordic Urothelial Cancer Oncology Group|Karolinska University Hospital Urothelial Carcinoma|Bladder Cancer|Renal Pelvis Cancer|Ureter Cancer|Urethra Cancer June 2012 Phase 1
NCT00534807 Bristol-Myers Squibb Cancer September 2007 Phase 1
NCT02665039 Dr Anders Ullén|Karolinska University Hospital Urothelial Carcinoma|Bladder Cancer|Renal Pelvis Cancer|Ureter Cancer|Urethra Cancer April 2014 Phase 2
NCT02845050 Association of Urogenital Oncology (AUO) Bladder Cancer July 2016 Phase 1|Phase 2
NCT00320073 UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific August 2006 Phase 1
NCT00251446 Veeda Oncology|Bristol-Myers Squibb Non-Small Cell Lung Cancer October 2005 Phase 2
NCT00389155 Bristol-Myers Squibb Bladder Cancer|Transitional Cell Carcinoma|Metastasis January 2007 Phase 2|Phase 3
NCT02347332 Pierre Fabre Medicament Recurrent or Metastatic Head and Neck Carcinoma April 2014 Phase 3
NCT01095003 Pierre Fabre Medicament Breast Cancer May 2009 Phase 3
NCT02054338 Pierre Fabre Medicament Advanced Breast Cancer June 2006 Phase 3
NCT00359476 Bristol-Myers Squibb Stomach Cancer March 2007 Phase 2|Phase 3
NCT00315237 Pierre Fabre Medicament|Bristol-Myers Squibb Transitional Cell Carcinoma of the Urothelial Tract|Bladder Cancer|Bladder Neoplasms July 2005 Phase 3
NCT00450515 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Breast Cancer March 2007 Phase 2
NCT01091168 Pierre Fabre Medicament Breast Cancer|Metastases September 2009 Phase 3
NCT02256436 Merck Sharp & Dohme Corp. Urothelial Cancer October 22, 2014 Phase 3
NCT02302807 Hoffmann-La Roche Bladder Cancer January 13, 2015 Phase 3
View MoreCollapse
Molecular Weight







Please store the product under the recommended conditions in the Certificate of Analysis.


Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: